Zydax performs well in efficacy study


In a large-scale study assessing the efficacy of Parnell Pharmaceutical Holdings' (PARN -4%) Zydax (sulfate ester) for the treatment of the clinical symptoms of canine osteoarthritis, 54% of the dogs treated with Zydax exhibited at least a 2.5-point reduction in PSS or PIS scores compared to 35% on placebo. The results were statistically significant (p = 0.01).

The company intends to commence a pivotal efficacy trial in October and expects to report results in 1H 2015.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs